CFD’er er komplekse instrumenter, og der er en stor risiko forbundet med disse for at miste penge på grund af gearing. 74.2 % af detailinvestorerne har tab på deres konto, når de handler CFD’er med denne udbyder.Du skal overveje, om du forstår, hvordan CFD’er fungerer, og om du har råd til at løbe en stor risiko for at miste dine penge.

Close

Handel Eli Lilly LLY

EliLilly live diagram

Grundlæggende Instrumenter

Weekly Search
Weekly
Daily
Dato Luk Ændring % Ændre Åbn Høj Lav

Seneste nyheder

Frances Wang 2025 Mar 25, 16:00

Central Banks Weigh Interest Rate Moves Amid Inflation Debate

Fed
Tommy Yap 2025 Mar 25, 16:00

Morning Note: S&P 500 Surges on Tariff Optimism as Tesla Jumps 10%

Morning Note S&P 500 TSLA Oil
Tommy Yap 2025 Mar 25, 16:00

Morning Note: Australia’s Inflation Cools, Japan’s Stays High, UK Awaits Data

Morning Note AUD USD JPY GBP
Frances Wang 2025 Mar 24, 16:00

Pepe coin news today: where will Pepe coin price go in 2025?

Cryptocurrencies
Frances Wang 2025 Mar 24, 16:00

USD/JPY news today: Will USD/JPY Break 150?

Forex
Tommy Yap 2025 Mar 23, 16:00

Morning Note: Nvidia’s $1 Trillion Data Centre Bet, SEC Crypto Rules, US PMI Data

Morning Note NVDA Cryptocurrencies CPI
Tommy Yap 2025 Mar 22, 16:00

Week Ahead: Investor Eyes on U.S. Inflation & Core PCE for Fed’s Next Move

Forex Indices
Frances Wang 2025 Mar 20, 16:00

Stock indices news: US stock indices rose on Fed decision

Indices

Info

Spread

6.19

Spread (%)

0.7439 %

Gearing

1:5

Dag til dag-rente Køb

-0.0597 %

Dag til dag-rente Sælg

-0.0292 %

Valuta

USD

Åbningstider for handel

Market åben

Onsdag

13:31 - 19:59

Mandag

13:31-19:59

Tirsdag

13:31-19:59

Torsdag

13:31-19:59

Fredag

13:31-19:59

Analyse og statistikker

Åbn

---

Forrige luk

---

52 uger høj/lav

--- – ---

Markedsværdi

776827240448

Aktier udestående

898169984

Indtjeningsdato (Næste)

1997-10-16

Udbytteprocent

2025-03-10

Ex-udbyttedato

2025-02-14

Forventet årlig udbyttesats

6

Forventet årlig udbytteprocent

0.0072

EPS

11.73

Få mere at vide om dette instrument

Eli Lilly Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Relaterede instrumenter

Aktiv
Sælge
Køb
% Ændre
Relaterede instrumenter
Trustpilot